Recursion Pharmaceuticals, Inc.(RXRX)NASDAQ
Company Profile & Information
Company Profile
Business overview, scale, and footprint
Business Overview
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Insider Transactions
Open-market activity and option exercises
150 insider transactions found. Showing 10 of 150 transactions.
| Insider Name | Relation to Company | Shares Changed | Price | Transaction Date |
|---|---|---|---|---|
| GIBSON CHRISTOPHER | Director | 40,000 | $178800.00 | Jan 20, 2026 |
| GIBSON CHRISTOPHER | Director | 40,000 | $N/A | Jan 20, 2026 |
| BORGESON BLAKE CHARLES | Director | 220,000 | $959200.00 | Jan 6, 2026 |
| GIBSON CHRISTOPHER | Director | 40,000 | $170000.00 | Jan 5, 2026 |
| GIBSON CHRISTOPHER | Director | 20,000 | $0.00 | Jan 5, 2026 |
| GIBSON CHRISTOPHER | Director | 60,000 | $N/A | Jan 5, 2026 |
| DAR ZAVAIN | Director | 3,571 | $0.00 | Jan 2, 2026 |
| LI DEAN Y | Director | 2,381 | $0.00 | Jan 2, 2026 |
| TAYLOR BEN R | Chief Financial Officer | 21,383 | $89381.00 | Dec 29, 2025 |
| KHAN NAJAT | Officer and Director | 124,403 | $548592.00 | Dec 22, 2025 |